NeoGenomics, Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Tony Zook; Other NEO average total compensation $3.81M.
- 2024-12-31: PEO Christopher Smith; PEO total compensation $11.34M; PEO compensation actually paid $10.32M; Other NEO average total compensation $2.81M.
- 2023-12-31: PEO Christopher Smith; PEO total compensation $11.67M; PEO compensation actually paid $16.41M; Other NEO average total compensation $3.41M.
- 2022-12-31: PEO Christopher Smith; Other NEO average total compensation $2.69M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Tony Zook | $3.81M | $1.57M | $22.00 | $125.00 | -$108.00M | adjusted EBITDA $43.00M | 2026-04-06 | ||
| 2024-12-31 | Christopher Smith | $11.34M | $10.32M | $2.81M | $2.21M | $56.00 | $118.00 | -$79.00M | $40.00M | 2026-04-06 |
| 2023-12-31 | Christopher Smith | $11.67M | $16.41M | $3.41M | $5.08M | $55.00 | $119.00 | -$88.00M | $3.00M | 2026-04-06 |
| 2022-12-31 | Christopher Smith | $2.69M | $1.91M | $32.00 | $114.00 | -$144.00M | -$48.00M | 2026-04-06 | ||
| 2021-12-31 | Mark Mallon | $4.04M | $2.55M | $117.00 | $126.00 | -$8.00M | -$4.00M | 2026-04-06 | ||
| 2024-12-31 | Christopher Smith | $11.34M | $10.32M | $2.81M | $2.21M | $56.00 | $118.00 | -$79.00M | adjusted EBITDA $40.00M | 2025-04-08 |
| 2023-12-31 | Christopher Smith | $11.67M | $16.41M | $3.41M | $5.08M | $55.00 | $119.00 | -$88.00M | $3.00M | 2025-04-08 |
| 2022-12-31 | Christopher Smith | $2.69M | $1.91M | $32.00 | $114.00 | -$144.00M | -$48.00M | 2025-04-08 | ||
| 2021-12-31 | Mark Mallon | $4.04M | $2.55M | $117.00 | $126.00 | -$8.00M | -$4.00M | 2025-04-08 | ||
| 2020-12-31 | Douglas VanOort | $4.12M | $14.72M | $972.62K | $2.32M | $184.00 | $126.00 | $4.00M | $35.00M | 2025-04-08 |
| 2023-12-31 | Christopher Smith | $11.67M | $16.41M | $3.00M | $4.43M | $55.00 | $119.00 | -$88.00M | adjusted EBITDA $3.00M | 2024-04-08 |
| 2022-12-31 | Christopher Smith | $2.69M | $1.91M | $32.00 | $114.00 | -$144.00M | -$48.00M | 2024-04-08 | ||
| 2021-12-31 | Mark Mallon | $4.04M | $2.55M | $117.00 | $126.00 | -$8.00M | -$4.00M | 2024-04-08 | ||
| 2020-12-31 | Douglas VanOort | $4.12M | $14.72M | $972.62K | $2.32M | $184.00 | $126.00 | $4.00M | $35.00M | 2024-04-08 |
| 2022-12-31 | $2.69M | $1.91M | $32.00 | $114.00 | -$144.00M | adjusted EBITDA -$48.00M | 2023-04-07 | |||
| 2021-12-31 | $4.04M | $2.55M | $117.00 | $126.00 | -$8.00M | -$4.00M | 2023-04-07 | |||
| 2020-12-31 | $4.12M | $14.72M | $972.62K | $2.32M | $184.00 | $126.00 | $4.00M | $35.00M | 2023-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |